Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $114.58, for a total value of $2,172,436.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Larry L. Wood also recently made the following trade(s):
- On Wednesday, November 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The stock was sold at an average price of $104.76, for a total value of $1,986,249.60.
Shares of Edwards Lifesciences Corp (NYSE:EW) opened at $114.22 on Monday. Edwards Lifesciences Corp has a 52-week low of $86.55 and a 52-week high of $121.45. The firm has a market capitalization of $24,175.47, a price-to-earnings ratio of 31.65, a PEG ratio of 2.04 and a beta of 0.51. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49.
Edwards Lifesciences announced that its board has authorized a stock repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.
A number of analysts recently issued reports on EW shares. Zacks Investment Research downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. BidaskClub downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Cowen restated a “buy” rating and issued a $135.00 price target on shares of Edwards Lifesciences in a research report on Thursday, October 12th. BMO Capital Markets restated a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. Finally, Deutsche Bank lowered their price target on Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Six equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $126.43.
Institutional investors have recently made changes to their positions in the company. ETF Managers Group LLC purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $112,000. MPS Loria Financial Planners LLC purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $140,000. Captrust Financial Advisors purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $149,000. Dupont Capital Management Corp purchased a new position in shares of Edwards Lifesciences during the third quarter valued at $142,000. Finally, Salem Investment Counselors Inc. increased its stake in shares of Edwards Lifesciences by 16.3% during the second quarter. Salem Investment Counselors Inc. now owns 1,419 shares of the medical research company’s stock valued at $168,000 after buying an additional 199 shares during the period. Hedge funds and other institutional investors own 81.82% of the company’s stock.
WARNING: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/18/insider-selling-edwards-lifesciences-corp-ew-vp-sells-2172436-80-in-stock.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.